Esophageal Clinical Trials

775 recruitingLast updated: June 20, 2026

There are 775 actively recruiting esophageal clinical trials across 57 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Houston, Texas, United States, New York, New York, United States, Shanghai, Shanghai Municipality, China. Updated daily from ClinicalTrials.gov.


Esophageal Trials at a Glance

775 actively recruiting trials for esophageal are listed on ClinicalTrialsFinder across 6 cities in 57 countries. The largest study group is Phase 2 with 280 trials, with the heaviest enrollment activity in Houston, New York, and Shanghai. Lead sponsors running esophageal studies include Fudan University, Mayo Clinic, and Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

Treatments under study

About Esophageal Clinical Trials

Looking for clinical trials for Esophageal? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Esophageal trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Esophageal clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 775 trials

Recruiting
Phase 1

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Triple-Negative Breast CancerEsophageal CancerPancreatic Cancer+11 more
Eli Lilly and Company420 enrolled34 locationsNCT06465069
Recruiting
Not Applicable

Evaluation of Skin Tests in Biotherapy Allergies

Colorectal, CancerCholangiocarcinomaEsophageal Squamous Cell Carcinoma+13 more
University Hospital, Angers70 enrolled1 locationNCT06971848
Recruiting
Phase 2

Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma

ChemotherapyRadiotherapyImmune Checkpoint Inhibitor+4 more
Chuangzhen Chen43 enrolled1 locationNCT07339488
Recruiting
Phase 2Phase 3

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

Gastroesophageal Junction AdenocarcinomaPeritoneal CarcinomatosisGastric Adenocarcinoma
ECOG-ACRIN Cancer Research Group148 enrolled55 locationsNCT07001748
Recruiting
Phase 1

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+10 more
National Cancer Institute (NCI)48 enrolled1 locationNCT06364410
Recruiting
Phase 1

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

MelanomaNon-small Cell Lung CancerMuscle-Invasive Bladder Carcinoma+1 more
Washington University School of Medicine64 enrolled1 locationNCT06529822
Recruiting
Phase 1

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

Triple-Negative Breast CancerColorectal, CancerNon-small Cell Lung Cancer+5 more
IDEAYA Biosciences150 enrolled15 locationsNCT07503808
Recruiting
Phase 2Phase 3

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+13 more
National Cancer Institute (NCI)224 enrolled372 locationsNCT06203600
Recruiting
Phase 1Phase 2

Study for AZD4360 in Participants With Advanced Solid Tumours

Gastric CancerGastroesophageal-junction CancerBiliary Tract Cancer+1 more
AstraZeneca117 enrolled18 locationsNCT06921928
Recruiting
Phase 1

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Triple-Negative Breast CancerPancreatic CancerNon-small Cell Lung Cancer+4 more
AbbVie694 enrolled46 locationsNCT05005403
Recruiting
Phase 2

TAIC FOLFOX for Locally Advanced G/GEJA

Gastroesophageal Junction AdenocarcinomaGastric Cancer (Diagnosis)
Guang'anmen Hospital of China Academy of Chinese Medical Sciences31 enrolled1 locationNCT07655024
Recruiting
Phase 3

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Gastroesophageal Junction AdenocarcinomaHER2-positive Gastric Cancer
AstraZeneca840 enrolled293 locationsNCT06764875
Recruiting
Not Applicable

The Application of Symptoms Management Program Based on the Patient Reported Outcome After Esophagectomy

Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences300 enrolled1 locationNCT07187154
Recruiting

Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining

Thoracic CancersLung Cancer NOSMalignant Pleural Mesotheliomas NOS+2 more
National Cancer Institute (NCI)1,559 enrolled1 locationNCT00242723
Recruiting

Postoperative Hypoxemia Increases the Risk of Anastomotic Leak After Radical Esophagectomy

Esophageal CarcinomaEsophageal AdenocarcinomaEsophagectomy+2 more
Sun Yat-sen University2,500 enrolled6 locationsNCT07309991
Recruiting
Phase 2

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

Gastroesophageal Adenocarcinoma
AstraZeneca100 enrolled70 locationsNCT07069712
Recruiting
Phase 1

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

Breast CancerColorectal, CancerEsophageal Cancer+3 more
Immunome, Inc.175 enrolled1 locationNCT07578571
Recruiting

Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy

Breast CarcinomaEsophageal CarcinomaHead and Neck Carcinoma+6 more
M.D. Anderson Cancer Center5,000 enrolled1 locationNCT00991094
Recruiting
Phase 1

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

Advanced Solid TumorMetastatic Solid TumorEsophageal Squamous Cell Carcinoma+7 more
Plexium, Inc.155 enrolled10 locationsNCT07284186
Recruiting
Phase 1Phase 2

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC298 enrolled43 locationsNCT06780111